Literature DB >> 12173121

National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

D R Snydman1, N V Jacobus, L A McDermott, R Ruthazer, E J C Goldstein, S M Finegold, L J Harrell, D W Hecht, S G Jenkins, C Pierson, R Venezia, J Rihs, S L Gorbach.   

Abstract

The results of a multicenter US survey using the National Committee for Clinical Laboratory Standards currently recommended methodology for measuring in vitro susceptibility of 2673 isolates of Bacteroides fragilis group species were compared from 1997 to 2000. The test panel consisted of 14 antibiotics: 3 carbapenems, 3 beta-lactam-beta-lactamase inhibitors, 3 cephamycins, 2 fluoroquinolones, clindamycin, chloramphenicol, and metronidazole. Declines in the geometric mean minimum inhibitory concentrations were seen with imipenem, meropenem, ampicillin-sulbactam, and the cephamycins. Increased geometric means were observed with the fluoroquinolones and were usually accompanied by an increase in resistance rates. Bacteroides distasonis shows the highest resistance rates among beta-lactam antibiotics, whereas Bacteroides vulgatus shows the highest resistance levels among fluoroquinolones. B. fragilis shows the lowest resistance rates for all antibiotics. All strains were susceptible to chloramphenicol and metronidazole concentrations <8 microgram/mL. The data underscore the need for species identification and continued surveillance to monitor resistance patterns.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173121     DOI: 10.1086/341934

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

Review 1.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

2.  Evaluation of 16S rRNA sequencing and reevaluation of a short biochemical scheme for identification of clinically significant Bacteroides species.

Authors:  Yuli Song; Chengxu Liu; Mauricio Bolanos; Julia Lee; Maureen McTeague; Sydney M Finegold
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains.

Authors:  Anastasia Katsandri; Joseph Papaparaskevas; Angeliki Pantazatou; Georgios L Petrikkos; Georgios Thomopoulos; Dimitra P Houhoula; Athina Avlamis
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 4.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.

Authors:  Carmen Betriu; Esther Culebras; María Gómez; Fátima López; Iciar Rodríguez-Avial; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

6.  Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia.

Authors:  Janessa M Smith; Edina Avdic; Pranita D Tamma; Long Zhang; Karen C Carroll; Sara E Cosgrove
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

7.  In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.

Authors:  Reiner Schaumann; Matthias Funke; Eva Janssen; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

8.  Do antimicrobial susceptibility patterns of colonic isolates of Bacteroides species change after antibiotic prophylaxis with cefoxitine during elective abdominal surgery?

Authors:  Nurver Ulger Toprak; Bahadir M Güllüoğlu; Ozlem Cakici; M Levhi Akin; Pakize Demirkalem; Tuncay Celenk; Güner Söyletir
Journal:  World J Surg       Date:  2005-10       Impact factor: 3.352

9.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; Y Golan; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; V Yu; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.